Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Q2 growth driven by strong performance from EntrestoⓇ,
KesimptaⓇ, PluvictoⓇ and KisqaliⓇ
Q2 sales
Entresto
Sales
USD million
Growth vs. PY
USD million
1,516
sacubitri/valsartan
Kesimpta
489
(ofatumumab)
240
PLUVICTO™
KISQALI
493
185
ribociclib
Ⓒ SCEMBLIX®
106
75
(asciminib)
LEQVIO®
78
56
150
64
A LUTATHERA
PROMACTA
583
49
(eltrombopag)
X PIQRAY
130
45
(alpelisib) tablets
Tafinlar. + Mekinist.
496
44
ILARIS
(canakinumab)
316
41
230
391
250
Growth vs. PY
CC
37%
GROWTH
105%
nm
Strong growth
(+71% cc);
66%
expected to continue
248%
249%
75%
11%
54%
13%
17%
Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
nm not meaningful.
5 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation